Business
Allergy Therapeutics shares key findings at EAACI
Allergy Therapeutics shares key findings at EAACI.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nAllergy Therapeutics shares key scientific findings from innovative research portfolio at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2023\n \n9 June 2023 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that the Group will be sharing key scientific findings from across its research portfolio at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place from today until 11 June 2023 in Hamburg, Germany.\n \nThe EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 12,000 clinicians, researchers, and allied health professionals, dedicated to improving the health of people affected by allergic diseases.\n \nAmong its nine posters being presented, Allergy Therapeutics will share:\n· Further clinical and preclinical studies on biomarker strategies, patient responses and the mechanism of action of allergy immunotherapies. Part of the data is derived from the positive G309 exploratory field study which evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. These findings supported the design of the ongoing pivotal Phase III Grass MATA MPL G306 trial, which is on track to report interim topline safety & efficacy data in Q4 2023.\n· Further pre-clinical data characterising the mechanism of action of the Group's novel virus-like particle (VLP) based peanut allergy vaccine candidate (\"VLP Peanut\"), which is currently being investigated in the Phase I PROTECT trial with plans on track for data later in 2023.\n· Preclinical studies examining allergenic venom homology, an area in which the Group is currently commercially active.\n \nAllergy Therapeutics will also be hosting a hybrid symposium, \"SCIT; pioneering a new era\", on Saturd...